AR090219A1 - Anticuerpos humanos frente a toxinas de clostridium difficile - Google Patents

Anticuerpos humanos frente a toxinas de clostridium difficile

Info

Publication number
AR090219A1
AR090219A1 ARP130100670A ARP130100670A AR090219A1 AR 090219 A1 AR090219 A1 AR 090219A1 AR P130100670 A ARP130100670 A AR P130100670A AR P130100670 A ARP130100670 A AR P130100670A AR 090219 A1 AR090219 A1 AR 090219A1
Authority
AR
Argentina
Prior art keywords
antibodies
difficile
toxin
human antibodies
clostridium difficile
Prior art date
Application number
ARP130100670A
Other languages
English (en)
Spanish (es)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR090219A1 publication Critical patent/AR090219A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
ARP130100670A 2012-03-02 2013-03-01 Anticuerpos humanos frente a toxinas de clostridium difficile AR090219A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605914P 2012-03-02 2012-03-02
US201261608255P 2012-03-08 2012-03-08
US201261717404P 2012-10-23 2012-10-23

Publications (1)

Publication Number Publication Date
AR090219A1 true AR090219A1 (es) 2014-10-29

Family

ID=47844536

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100670A AR090219A1 (es) 2012-03-02 2013-03-01 Anticuerpos humanos frente a toxinas de clostridium difficile

Country Status (18)

Country Link
US (2) US9399674B2 (enExample)
EP (1) EP2820044A1 (enExample)
JP (2) JP2015509962A (enExample)
KR (1) KR20140130709A (enExample)
CN (2) CN108101983A (enExample)
AR (1) AR090219A1 (enExample)
AU (1) AU2016203511A1 (enExample)
BR (1) BR112014021251A2 (enExample)
CA (1) CA2863536A1 (enExample)
HK (1) HK1200463A1 (enExample)
IL (1) IL233884A0 (enExample)
MX (1) MX2014010527A (enExample)
NZ (2) NZ714516A (enExample)
RU (2) RU2628305C2 (enExample)
SG (2) SG11201405087PA (enExample)
TW (1) TWI592422B (enExample)
UY (1) UY34652A (enExample)
WO (1) WO2013130981A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9181632B1 (en) 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
CA2976976C (en) 2015-02-19 2023-02-28 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
EP3283103A4 (en) * 2015-04-15 2018-12-05 Medimmune, LLC Methods for treating clostridium difficile infection and associated disease
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
EP3448987A4 (en) * 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
US20210032351A1 (en) * 2017-12-13 2021-02-04 Xdcexplorer (Shanghai) Co., Ltd. Egfrviii antibody and conjugate, and preparation method and use thereof
US11992520B2 (en) 2018-09-18 2024-05-28 Vanderbilt University Human monoclonal antibodies to Staphylococcal aureus Isd proteins and uses thereof
US20200148762A1 (en) * 2018-11-09 2020-05-14 Avamab Pharma Inc. Methods for regulating endogenous production of antibodies against infectious diseases
CN111793130B (zh) * 2019-03-20 2021-09-14 华中农业大学 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
WO2021219786A1 (en) * 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile
US20260092101A1 (en) * 2024-10-02 2026-04-02 The Regents Of The University Of Colorado, A Body Corporate Method for treating sepsis and related diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5224657A (en) 1989-05-23 1993-07-06 Kabushiki Kaisha Toshiba Cryogenic refrigerator
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
CA2219361C (en) * 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
CN1809591A (zh) * 2003-05-21 2006-07-26 米德列斯公司 针对炭疽芽孢杆菌保护性抗原的人单克隆抗体
ES2366626T3 (es) 2004-02-06 2011-10-24 University Of Massachusetts Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
CA2592015A1 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
WO2007123850A2 (en) * 2006-04-17 2007-11-01 Schering-Plough Ltd. Recombinant attenuated clostridium organisms and vaccine
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
JP5345532B2 (ja) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Ｌｃｔ中毒に対する医薬品
US8084684B2 (en) 2006-10-09 2011-12-27 Solexel, Inc. Three-dimensional thin-film solar cells
US20110020356A1 (en) 2007-12-07 2011-01-27 Lin Fang Therapeutic clostridium difficile antibody compositions
EP2271366A4 (en) 2008-02-28 2012-06-20 3M Innovative Properties Co ANTIBODIES DIFFICULT CLOSTRIDIUM SPORES AND USES THEREOF
US8709428B2 (en) 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
ES2660008T3 (es) * 2009-09-23 2018-03-20 Thomas Julius Borody Terapia para infecciones entéricas crónicas
WO2011063346A1 (en) 2009-11-20 2011-05-26 Northshore University Health System Research Institute Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
AU2011239470B2 (en) 2010-04-15 2015-09-10 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease

Also Published As

Publication number Publication date
US20130230531A1 (en) 2013-09-05
UY34652A (es) 2013-09-02
JP2018029625A (ja) 2018-03-01
RU2017127772A (ru) 2019-02-04
TW201350501A (zh) 2013-12-16
CN108101983A (zh) 2018-06-01
BR112014021251A2 (pt) 2017-06-27
KR20140130709A (ko) 2014-11-11
IL233884A0 (en) 2014-09-30
SG11201405087PA (en) 2014-09-26
SG10201610123UA (en) 2017-01-27
AU2013203942A1 (en) 2013-09-19
US9399674B2 (en) 2016-07-26
TWI592422B (zh) 2017-07-21
US20160264650A1 (en) 2016-09-15
WO2013130981A1 (en) 2013-09-06
AU2013203942B2 (en) 2016-03-10
RU2014139552A (ru) 2016-04-20
RU2628305C2 (ru) 2017-08-15
AU2016203511A1 (en) 2016-06-16
HK1200463A1 (en) 2015-08-07
AU2013203942A8 (en) 2016-08-11
NZ628943A (en) 2016-08-26
NZ714516A (en) 2017-06-30
CN104203976A (zh) 2014-12-10
JP2015509962A (ja) 2015-04-02
MX2014010527A (es) 2014-10-14
EP2820044A1 (en) 2015-01-07
CA2863536A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
HK1200463A1 (en) Human antibodies to clostridium difficile toxins
CL2014000491A1 (es) Anticuerpos monoclonales neutralizantes de las exotoxinas tcda y/o tcdb de clostridium difficile; composición farmacéutica que los comprende; y uso para tratar infección por c. difficile.
ECSP17041865A (es) Anticuerpos anti-cd47 y usos de los mismos
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
MX2014000373A (es) Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y el virus de influenza b.
BR112017003582A2 (pt) anticorpos, composições e usos
MX2015000999A (es) Anticuerpos anti kit y usos de los mismos.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CO2019006902A2 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
MX2014000749A (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
ECSP14013132A (es) Anticuerpos anti-psgl-1 y usos de los mismos
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
UY34327A (es) ?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan 4-hidrofenil-piruvato-dioxigenasa?.
CR20170031A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
MX358099B (es) Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.
MX392533B (es) Anticuerpos humanos contra glicoproteina del virus ebola.
PE20141821A1 (es) Composiciones herbicidas que contienen bentazon y el inhibidor als y el inhibidor accasa
EA201400447A1 (ru) АНТИТЕЛА К CD1d
MX2016016992A (es) Aptameros especificos de tlr-4 y usos de los mismos.
MX378368B (es) Receptores de antigeno y usos de los mismos.
MX2015003701A (es) Composiciones para tratamiento.
MX378749B (es) Agentes para neutralizacion de influenza.

Legal Events

Date Code Title Description
FB Suspension of granting procedure